Candesartan as a tentative treatment for COVID-19: A prospective non-randomized open-label study
| Autor: | Theo Audi Yanto Lemuel, Antonia Anna Lukito, Allen Widysanto, Irawan Yusuf, Billy Massie, Ignatius Bima Prasetya, Mira Yuniarti, Nicolaski Lumbuun, Raymond Pranata, Eka Julianta Wahjoepramono, Cindy Meidy |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Microbiology (medical) medicine.medical_specialty 030106 microbiology Tetrazoles Infectious and parasitic diseases RC109-216 Article Severity 03 medical and health sciences Angiotensin 0302 clinical medicine Internal medicine Intensive care medicine Humans 030212 general & internal medicine Prospective Studies Prospective cohort study ComputingMethodologies_COMPUTERGRAPHICS business.industry Proportional hazards model Candesartan SARS-CoV-2 Hazard ratio Biphenyl Compounds COVID-19 General Medicine Confidence interval Biphenyl compound Coronavirus Regimen Infectious Diseases Treatment Outcome Benzimidazoles business medicine.drug |
| Zdroj: | International Journal of Infectious Diseases, Vol 108, Iss, Pp 159-166 (2021) International Journal of Infectious Diseases |
| ISSN: | 1201-9712 |
| Popis: | Graphical abstract Background This study aimed to investigate whether the addition of candesartan to the standard care regimen improved the outcome in patients with coronavirus 2019 (COVID-19). Methods A prospective non-randomized open-label study was undertaken from May to August 2020 on 75 subjects (aged 18–70 years) hospitalized in Siloam Kelapa Dua Hospital. Uni- and multi-variable Cox regression analyses were performed to obtain hazard ratios (HRs). The primary outcomes were: (1) length of hospital stay; (2) time to negative swab; and (3) radiological outcome (time to improvement on chest X ray). Results None of the 75 patients with COVID-19 required intensive care. All patients were angiotensin-receptor-blocker naïve. In comparison with the control group, the candesartan group had a significantly shorter hospital stay [adjusted HR 2.47, 95% confidence interval (CI) 1.16–5.29] after adjusting for a wide range of confounders, and no increased risk of intensive care. In the non-obese subgroup, the candesartan group had a shorter time to negative swab (unadjusted HR 2.11, 95% CI 1.02–4.36; adjusted HR 2.40, 95% CI 1.08–5.09) and shorter time to improvement in chest x ray (adjusted HR 2.82, 95% CI 1.13–7.03) compared with the control group. Conclusion Candesartan significantly reduces the length of hospital stay after adjustment for covariates. All primary outcomes improved significantly in the non-obese subgroup receiving candesartan. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|